Enzo Biochem Announces New Validated Cost-Effective Cervical Cancer Biomarker Detection Test
January 22 2018 - 8:00AM
Business Wire
Product is Latest Addition to Fast Growing
Line of Quality Tests Designed to Bolster Clinical Diagnostics
Profit Margins Amidst Declining Reimbursement Rates
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics
company, announced today validation of a cervical cancer biomarker
detection test that provides a highly robust and cost-efficient
solution for anatomical pathology.
Specifically, Enzo’s validated p16, a marker used extensively as
a key diagnostic and prognostic biomarker of several cancers, is
the latest addition to the company’s growing immunohistochemistry
pipeline, including, among others, Ki-67, Her2 and p53.
Enzo’s validated p16 provides clear detection of tissue
abnormalities in the field of cancer diagnostics, including
cervical cancer’s progression. It complements the company’s
POLYVIEW® immunochemistry detection, the recent subject of a
favorable article in the prestigious peer-reviewed Annals of
Diagnostic Pathology. The article cited POLYVIEW® as having no
false-positives in tests unlike some of the leading products in the
field, which were found to have large percentages of
false-positives that could lead to unnecessary, costly and
time-consuming interventions.
With current mounting cost and reimbursement pressures, Enzo’s
new p16 test provides a highly cost-effective alternative. Other
p16 tests on the market have of late become unaffordable as a
result of increasing reagent costs outweighing average
reimbursements. When p16 is used in combination with Enzo’s
POLYVIEW® detection system’s reduction of false-positives, the
economics are substantially enhanced. This and other similar
compounds comprise a $200 million market.
In an era of high product costs and shrinking reimbursements,
Enzo has positioned itself as a growing provider of high quality,
cost-effective tests that provide value in bolstering diagnostics
profit margins.
“We launched our immunohistochemistry tests in response to
market leaders raising prices,” said Elazar Rabbani, Ph.D., Enzo
CEO and Chairman. “By developing our own p16, Ki-67, and p53 tests,
among others, and the fact that we have a truly unique integrated
capability to develop, evaluate and manufacture these and other
diagnostics, we believe we can alleviate pressure on clinical labs
by providing low cost, clinically relevant products and services,
which is what we are engaged in doing.”
The expanded Anatomical Pathology global program at Enzo offers
cost-effective clinically relevant solutions, enhances Enzo’s
ongoing collaborations with clinical partners, and expands the
company’s clinical and reference services nationwide. This
complements Enzo’s long standing position within the women’s health
field with a focus on cervical cancer testing dating back to the
launch of the first in situ HPV cervical cancer detection system in
the early 1980’s. In addition to these products, Enzo’s portfolio
includes a line of assays for identification of women’s health
infectious diseases as well as for the quantification of viral load
in serum or plasma specimens.
About Enzo Biochem
Enzo Biochem is a pioneer in molecular diagnostics, leading the
convergence of clinical laboratories, life sciences and
intellectual property through the development of unique diagnostic
platform technologies that provide numerous advantages over
previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products, systems and
services that meet the ever-changing and rapidly growing needs of
health care today and into the future. Underpinning Enzo Biochem’s
products and technologies is a broad and deep intellectual property
portfolio, with patent coverage across a number of key enabling
technologies.
Except for historical information, the matters discussed in this
news release may be considered "forward-looking" statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as
amended. Such statements include declarations regarding the intent,
belief or current expectations of the Company and its management,
including those related to cash flow, gross margins, revenues, and
expenses which are dependent on a number of factors outside of the
control of the Company including, inter alia, the markets for the
Company’s products and services, costs of goods and services, other
expenses, government regulations, litigation, and general business
conditions. See Risk Factors in the Company’s Form 10-K for the
fiscal year ended July 31, 2017. Investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve a number of risks and uncertainties that
could materially affect actual results. The Company disclaims any
obligations to update any forward-looking statement as a result of
developments occurring after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180122005402/en/
For: Enzo Biochem, Inc.Steve Anreder,
212-532-3232steven.anreder@anreder.comorCEOcast, Inc.Michael Wachs,
212-732-4300mwachs@ceocast.com
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2024 to May 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From May 2023 to May 2024